Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA284692
Max Phase: Preclinical
Molecular Formula: C13H16ClN3O2
Molecular Weight: 246.29
Molecule Type: Small molecule
Associated Items:
ID: ALA284692
Max Phase: Preclinical
Molecular Formula: C13H16ClN3O2
Molecular Weight: 246.29
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cn1cc[n+](COCc2ccccc2)c1/C=N/O.[Cl-]
Standard InChI: InChI=1S/C13H15N3O2.ClH/c1-15-7-8-16(13(15)9-14-17)11-18-10-12-5-3-2-4-6-12;/h2-9H,10-11H2,1H3;1H
Standard InChI Key: PRSGGQYVNLJACX-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 246.29 | Molecular Weight (Monoisotopic): 246.1237 | AlogP: 1.29 | #Rotatable Bonds: 5 |
Polar Surface Area: 50.63 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 7.02 | CX Basic pKa: | CX LogP: -1.78 | CX LogD: -2.25 |
Aromatic Rings: 2 | Heavy Atoms: 18 | QED Weighted: 0.37 | Np Likeness Score: -0.32 |
1. Bedford CD, Harris RN, Howd RA, Miller A, Nolen HW, Kenley RA.. (1984) Structure-activity relationships for reactivators of organophosphorus-inhibited acetylcholinesterase: quaternary salts of 2-[(hydroxyimino)methyl]imidazole., 27 (11): [PMID:6492073] [10.1021/jm00377a010] |
2. Bedford CD, Harris RN, Howd RA, Goff DA, Koolpe GA, Petesch M, Miller A, Nolen HW, Musallam HA, Pick RO.. (1989) Quaternary salts of 2-[(hydroxyimino)methyl]imidazole. 2. Preparation and in vitro and in vivo evaluation of 1-(alkoxymethyl)-2-[(hydroxyimino)methyl]-3-methylimida zolium halides for reactivation of organophosphorus-inhibited acetylcholinesterases., 32 (2): [PMID:2913310] [10.1021/jm00122a034] |
3. Bedford CD, Harris RN, Howd RA, Goff DA, Koolpe GA, Petesch M, Koplovitz I, Sultan WE, Musallam HA.. (1989) Quaternary salts of 2-[(hydroxyimino)methyl]imidazole. 3. Synthesis and evaluation of (alkenyloxy)-, (alkynyloxy)-, and (aralkyloxy)methyl quaternarized 2-[(hydroxyimino)methyl]-1-alkylimidazolium halides as reactivators and therapy for soman intoxication., 32 (2): [PMID:2913311] [10.1021/jm00122a035] |
Source(1):